Dermal penetration enhancers and drug delivery systems involving same
DC CAFCFirst Claim
1. A transdermal drug delivery system which comprises:
- a therapeutically effective amount of at least one physiologically active agent; and
at least one dermal penetration enhancer present in an amount of from 10 to 10,000 wt % based on the weight of the active agent;
wherein the dermal penetration enhancer is at least one of a safe skin-tolerant ester sunscreen of formula (I);
wherein R3 is hydrogen, lower alkyl, lower alkoxy, halide, hydroxy or NR3R4;
R2 is a C8 to C18 alkyl, R3 and R4 are each independently hydrogen, lower alkyl or R3 and R4 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring;
n is 0 or 1, and q is 1 or 2, wherein when n is 0 and R1 is NR3R4, then NR3R4 is para-substituted.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
450 Citations
25 Claims
-
1. A transdermal drug delivery system which comprises:
-
a therapeutically effective amount of at least one physiologically active agent; and
at least one dermal penetration enhancer present in an amount of from 10 to 10,000 wt % based on the weight of the active agent;
wherein the dermal penetration enhancer is at least one ofa safe skin-tolerant ester sunscreen of formula (I);
whereinR3 is hydrogen, lower alkyl, lower alkoxy, halide, hydroxy or NR3R4;
R2 is a C8 to C18 alkyl, R3 and R4 are each independently hydrogen, lower alkyl or R3 and R4 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring;
n is 0 or 1, and q is 1 or 2, wherein when n is 0 and R1 is NR3R4, then NR3R4 is para-substituted. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A non-occlusive, percutaneous or transdermal drug delivery system which comprises:
-
(i) a therapeutically effective amount of at least one physiologically active agent;
(ii) at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen, and is present in an amount of from 10 to 10,000 wt % based on the weight of the active agent;
(iii) at least one volatile liquid present in an amount to act as a vehicle for the active agent and penetration enhancer;
wherein;
the dermal penetration enhancer (A) is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent within said surface or membrane, and (B) is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal; and
,after application of the system to an area of the dermal surface, the area becomes touch-dry within 3 minutes of application. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
wherein R1 is hydrogen, lower alkyl, lower alkoxy, halide, hydroxy or NR3R4;
R2 is a long chain alkyl;
R3 and R4 are each independently hydrogen, lower alkyl or R3 and R4 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring;
n is 0 or 1; and
q is 1 or 2.
-
-
17. A drug delivery system according to claim 14, wherein said ester is a long chain alkyl para-aminobenzoate, long chain alkyl dimethyl-para-aminobenzoate, long chain alkyl cinnamate, long chain alkyl methoxycinnamate or long chain alkyl salicylate.
-
18. A drug delivery system according to claim 17, wherein said ester is octyl dimethyl-para-aminobenzoate, octyl para-methoxycinnamate or octyl salicylate.
-
19. A drug delivery system according to claim 15, wherein the volatile liquid is ethanol or isopropanol.
-
20. A drug delivery system according to claim 15, wherein the physiologically active agent is a steroid, hormone derivative, non-steroidal anti-inflammatory drug, opioid analgesic, antinauseant, antioestrogen, aromatase inhibitor, 5-alpha reductase inhibitor, anxiolytic, prostaglandin, anti-viral drug, anti-migraine compound, antihypertensive agent, anti-malarial compound, bronchodilator anti-depressant, anti-alzheimer'"'"'s agent, neuroleptic and antipsychotic agent, anti-parkinson'"'"'s agent, antiandrogen or anorectic agent.
-
21. A drug delivery system according to claim 15, wherein the physiologically active agent is testosterone, oestradiol, ethinyloestradiol, progesterone, norethisterone acetate, ibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, fentanyl, buprenorphine, scopolamine, prochlorperazine, metochlopramide, ondansetron, tamoxifen, epitiostanol, exemestane, 4-hydroxy-androstenedione and its derivatives, finasteride, turosteride, LY191704, MK-306, alprazolam, alprostadil, prostacylcin and its derivatives, melatonin, n-docosanol, tromantadine, lipophilic pro-drugs of acyclovir, low molecular weight heparin, enoxaparin, sumatriptan, amlodipine, nitrendipine, primaquine, minoxidil, minoxidil pro-drugs, pilocarpine, salbutamol, terbutaline, salmeterol, ibogaine, bupropian, rolipram, tacrine, fluphenazine, haloperidol, N-0923, cyproterone acetate or mazindol.
-
22. A drug delivery system according to claim 14, wherein the system is applied to the dermal surface by an aerosol, as a spray.
-
23. A drug delivery system according to claim 22, wherein the aerosol is a fixed or variable metered dose aerosol.
-
24. A drug delivery system according to any one of claim 15, further comprising a pharmaceutical compounding agent, co-solvent, surfactant, emulsifier, antioxidant, preservative, stabiliser, diluent or a mixture of two or more of said components.
-
25. A transdermal drug delivery system according to claim 14, wherein the physiologically active agent or prodrug thereof, the dermal penetration enhancer, and the volatile liquid are a single phase.
Specification